Integrated datasets of proteomic and metabolomic biomarkers to predict its impacts on comorbidities of type 2 diabetes mellitus by Cheema, Amrita K. et al.
OR I G I N A L R E S E A R C H
Integrated Datasets of Proteomic and
Metabolomic Biomarkers to Predict Its Impacts on
Comorbidities of Type 2 Diabetes Mellitus
This article was published in the following Dove Press journal:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Amrita K Cheema1
Prabhjit Kaur1
Amina Fadel2
Noura Younes3
Mahmoud Zirie4
Nasser M Rizk 2,5
1Department of Oncology, Lombardi
Comprehensive Cancer Center at
Georgetown University Medical Center,
Washington, DC, USA; 2Biomedical
Sciences Department, College of Health
Sciences and Biomedical Research
Center, QU Health, Qatar University,
Doha, Qatar; 3Clinical Chemistry Lab,
Hamad Medical Corporation, Doha,
Qatar; 4Endocrine Department, Hammad
Medical Corporation, Doha, Qatar;
5Physiology Department, Mansoura
Faculty of Medicine, Mansoura, Egypt
Objective: The objective of the current study is to accomplish a relative exploration of the
biological roles of differentially dysregulated genes (DRGs) in type 2 diabetes mellitus
(T2DM). The study aimed to determine the impact of these DRGs on the biological pathways
and networks that are related to the associated disorders and complications in T2DM and to
predict its role as prospective biomarkers.
Methods: Datasets obtained from metabolomic and proteomic profiling were used for
investigation of the differential expression of the genes. A subset of DRGs was integrated
into IPA software to explore its biological pathways, related diseases, and their regulation in
T2DM. Upon entry into the IPA, only 94 of the DRGs were recognizable, mapped, and
matched within the database.
Results: The study identified networks that explore the dysregulation of several functions;
cell components such as degranulation of cells; molecular transport process and metabolism
of cellular proteins; and inflammatory responses. Top disorders associated with DRGs in
T2DM are related to organ injuries such as renal damage, connective tissue disorders, and
acute inflammatory disorders. Upstream regulator analysis predicted the role of several
transcription factors of interest, such as STAT3 and HIF alpha, as well as many kinases
such as JAK kinases, which affects the gene expression of the dataset in T2DM. Interleukin 6
(IL6) is the top regulator of the DRGs, followed by leptin (LEP). Monitoring the dysregula-
tion of the coupled expression of the following biomarkers (TNF, IL6, LEP, AGT, APOE, F2,
SPP1, and INS) highlights that they could be used as potential prognostic biomarkers.
Conclusion: The integration of data obtained by advanced metabolomic and proteomic
technologies has made it probable to advantage in understanding the role of these biomarkers
in the identification of significant biological processes, pathways, and regulators that are
associated with T2DM and its comorbidities.
Keywords: type 2 diabetes mellitus, pathway analysis, regulators, biomarkers, disorders,
bioinformatics
Plain Summary
In summary, the incorporation of metabolomic and proteomic data through integrative pathway
analysis using different tools would help in understanding the role of various biomarkers in the
identification of the biological processes, pathways, upstream regulators, and pathophysiology
that are associated with Type 2 Diabetes Mellitus (T2DM) and comorbidities. Therefore, such
a study could help to recognize those patients at higher risk for a specific complication and its
response to a particular class of anti-diabetic drugs. This study could help in personalized
medicine for T2DM.
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Introduction
Recent decades had indicated a remarkable upsurge in the
prevalence of diabetes mellitus (DM) worldwide, particu-
larly of type 2 diabetes.1 Type 2 Diabetes Mellitus
(T2DM) is the most diagnosed form of diabetes character-
ized by insulin resistance, impaired β-cell function, hyper-
glycemia, and some comorbidities, including obesity and
cardiovascular disease.2 The potential impact of diabetes
on health, health care system, financial cost, and life
expectancy increases in the upcoming years. Optimum
treatment of T2DM requires a set of potentially multiple
measures to manage hyperglycemia, hyperlipidemia, and
to address the risk factors for the array of diabetic
complications.
Identification of biomarkers for T2DM and its compli-
cations is a challenging issue because of the diverse nature
of this disease. Different factors contribute to the hetero-
genicity of type DM such as the glycemic control, treat-
ment response, duration of the diseases, age of onset and
biochemical profile, body mass index, and variations in
environmental exposures, which could affect the disease
diversity.3 Biomarkers are needed for the evaluation of
chemical profiles, disease status, target validation, and
treatment regimens. Advances in proteomics and meta-
bolic profiling have increased the screening for experimen-
tal biomarkers. Serum biomarkers currently exist for
T2DM, but it remains a challenge to evaluate pathophy-
siology on a patient by patient basis. Therefore, novel
biomarkers based on the integration of different profiles
such as metabolomics, proteomics, and transcriptomics
would better reflect the regulation of gene expression and
the biologic process in diabetes for preventative strategies
and lessen the complications are needed.
Metabolites symbolize intermediate and end products of
metabolic pathways that reflect the physiology and dysfunc-
tions of metabolic processes and disorders. Recent technol-
ogy allows for the assessment of metabolites opening new
opportunities to study changes in biochemical pathways for
insight into the biological mechanisms of disorders such as
T2DM and its comorbidities.4 This integration constitutes the
promise of personalized medicine (PM).
The personalized medicine could help in the screening of
subjects at risk of developingT2DM, aswell as one or all of the
complicating morbidities associated with microangiopathies,
such as retinopathy, neuropathy, nephropathy, and macroan-
giopathy or large-vessel disease. They also have the potential
to direct treatment planning, regarding personalized goal set-
ting, choice of treatments, and treatment prioritization.5
In this study, the aim is to accomplish a comparative
and integrative investigation of metabolomic and proteo-
mic datasets of gene expression to identify differentially
regulated genes (DRGs) as potential predictive biomarkers
associated with type 2 diabetes and its complications. The
integration of the dataset of DRGs is used to reveal sig-
nificant pathways and biological functions and diseases
that are relevant to understand the pathogenesis of asso-
ciated comorbidities of diabetes and its complications. The
study pursued to recognize biological processes and meta-
bolic pathways of DRGs, which are interrelated to T2DM
that were differentially up- or downregulated in compar-
ison to healthy controls. Therefore, the overall target of the
current study is to recognize those patients at higher risk
for a disorder or complication associated with T2DM
through understanding the biological networks and path-
ways underlie these diseases that could respond better to
management and drug treatment.
Methodology
Study Selection and Sample Collection
Datasets from two previously published studies on T2DM by
our group were selected for gene expression integration.5,6
Each gene was described by fold change. All data was col-
lected from serum/plasma samples of patients at the Hamad
Medical Hospital, Qatar (HMC) with T2DM versus a healthy
control group, all subjects were unrelated Arab subjects of
different countries to ensure lack of inheritance. A total of
140 subjects were involved in the present study, of which 85
T2DM subjects and 55 healthy controls, non-diabetics. T2DM
was diagnosed by themedical team of the diabetic unit (HMC)
according to the American Diabetes Association (ADA) cri-
teria, consisting of fasting plasma glucose ≥ 126 mg/dL
(≥6.993 mmol/L), 2 hr. plasma glucose ≥200 mg/dL (11.1
mmol/L) during an oral glucose tolerance test and/or HbA1C
≥ 6.5%.7 The diagnostic criteria were based on the diagnostic
standards based on oral GTT following ADA diagnostic cri-
teria to be sure that all study subjects, including the controls,
are not pre-diabetic or diabetic. The age of diabetic patients
was older than the age of the control, but thiswas accounted for
in the current study as we compared the data using AUC, and a
Supplementary Table 1was provided. The studywas approved
by the Institutional Review Board of the Hamad Medical
Corporation, Qatar University, and Georgetown University
(HMC approval number 8249/08, QU-IRB-06/09 and
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2008–538, respectively). The study was performed according
to the principles expressed in the Declaration of Helsinki.
Written informed consent was obtained from each subject
after a full explanation of the purpose, nature, and risk of all
procedures used.
After overnight fasting, venous blood was collected as
previously described.5 Serum, plasma, and buffy coat were
separated from the whole blood and stored at −80ºC within
4 hours of collection. For maximum longevity and to avoid
repeated freeze-thaw cycles, the plasma, and serum sam-
ples were aliquoted extensively and stored at −80ºC till
further use.5
For the metabolomic and lipidomic profiling experiment
levels of high-density lipoprotein cholesterol, total choles-
terol, and triglycerides were assayed by automated clinical
laboratory methods using a diagnostic analyzer. Low den-
sity lipoprotein cholesterol levels were estimated using the
Friedewald formula: LDL-C = TC – HDL-C (TG/5).8
Serum aminotransferase, albumin, alkaline phosphatase,
and creatinine were also assayed using a diagnostic analyzer
at HMC as previously published.9,10 Metabolite extraction
from plasma was done by adding 175 µL of 66% acetoni-
trile (in water) containing internal standards to 25 µL of
plasma. The samples were incubated on ice for 15 minutes
and centrifuged at 14,000 rpm at 4ºC for 20 minutes. The
supernatant was transferred to a fresh tube and dried under
a vacuum. The dried samples were resuspended in 100 µL
of solvent A (98% water and 2% acetonitrile) for UPLC-
ESI-Q-TOF-MS analysis. In order to increase metabolome
coverage, plasma lipidomics was performed by extracting
lipids using the method described by.11
For the protein expression profiling experiment, serum
samples were delipidated according to the protocol
described by Cham and Knowles in preparation for
iTRAQ analysis.12 ProteoExtract Albumin/IgG (from
Calbiochem), and Vivapure anti-HSA-IgG kits were used
to evaluate the efficiency of high abundance protein deple-
tion from serum samples. Total protein concentration was
calculated by the Bradford Assay. The Vivapure anti-HSA
/IgG kit was used for the iTRAQ experiment.
Data Processing and Metabolite
Identification
Centroided and integrated UPLC-TOFMS data were pre-
processed using the XCMS software and normalized to the
ion intensity of the respective internal standards for the
metabolomic and lipidomic profiling experiment.13
Multivariate analyses were performed to delineate signifi-
cantly altered metabolites. The metabolites were identified
via accurate mass-based search using the Madison
Metabolomics Consortium Database (MMCD),14 the
Human Metabolome Database (HMDB),15 and LIPID
MAPS. The lipids with significant fold change in T2DM
as compared to the control group were identified via
a spectral matching based lipid identification software,
SimLipid v 3.0 and LIPID MAPS,16 and confirmed against
fragmentation pattern of standards. Metabolite identifica-
tions confirmed by comparing the retention time under the
same chromatographic conditions and by matching the
fragmentation pattern of the parent ion from the biological
sample to that of the standard metabolite using tandem
mass spectrometry (UPLC-TOFMS/MS).
Nano-UPLC-MS/MS and iTRAQ Analysis
Nano UPLC-MS/MS analysis was conducted by an elec-
trospray quadrupole time of flight (ESI-QTOF) mass spec-
trometer coupled with a Nano-Acquity-UPLC system.
Relative abundance quantitation, peptide, and protein iden-
tifications were performed using Protein Pilot software 3.0
(ABSCIEX). Data were analyzed with MMTS as a fixed
modification of cysteine, and the database was searched
with a 95% confidence interval rate for protein identifica-
tions. High confidence peptides of the target proteins exhi-
biting rich production spectrum were selected for multiple
reaction monitoring (MRM) assays. MRM data were pro-
cessed using TargetLynx 2.0, while Graph Pad Prism pro-
gram v 5.0 was used for statistical analysis and to generate
the receiver operating characteristics. The Wilcoxon test
was used for the comparison of each peptide.
Luminex Analysis
The serum samples of the study subjects (Diabetics and
controls) were used to evaluate the different panels of
biomarkers, including the inflammatory, adipokines, oxi-
dative stress, metabolic, CVD, and bone markers. The
following kits were used to evaluate such different panels,
including the following multiplex assays, HMHMAG-34,
HCVD1-67AK, APOMAG-62K, HADK1MAG-61k-03,
HBN1A-51K, and HCVD2MAG-67K. All assays were
performed in triplicates according to the manufacturer’s
instructions from Millipore (Merck Millipore, Billerica,
MA, USA). The assays were performed using
a Luminex200 (Austin, TX, USA). Of note, PCA analysis
was performed for all dataset of the study to obtain DRGs
as we previously published.5,6
Dovepress Cheema et al
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Statistical Analyses
Clinical and biochemical data are expressed as mean ± SD.
All statistical analyses were performed using the SPSS
program for Windows (version 21 statistical software:
Texas instruments, IL, USA). Differences between control
and T2DM were performed using Student’s t-test or
Mann–Whitney/Wilcoxon when appropriate. ANCOVA
was used to perform analysis, including the age to com-
pare the biochemical data of the study subjects and AUC
(see Supplementary Table 1). Two-tailed p value is sig-
nificant when p < 0.05.
Bioinformatic Analysis
Ingenuity Pathway Analysis (IPA; http://www.ingenuity.
com/) was performed to identify canonical pathways, dis-
eases and functions, and gene networks that are most
significant to the dataset and to categorize differentially
dysregulated genes in specific diseases and functions. We
also used Pathway Studio 9 (Elsevier) for Integrated path-
way mapping. For Network generation, a data set contain-
ing gene/protein/metabolite identifier and corresponding
fold change and UniProt ID was uploaded into the appli-
cation. Each protein/metabolite ID was mapped to its
corresponding gene/protein/metabolite in the Ariadne
ResNet Mammalian database. The metabolites were
grouped based on their fold change and used to develop
networks based on regulation and connectivity.
Results
Clinical Data of the Study Subjects
The characteristics of the study population are described in
Table 1. As shown in Table 1, diabetic subjects have sig-
nificantly higher values for age, BMI, glucose, HbA1c%,
estimated average glucose (eAC), triglycerides, ALT, and
CRP than control healthy subjects. Diabetic subjects have
significantly lower values for C-peptide and insulin than
healthy control subjects. Other variables are not significantly
different between the two studied groups.
Differentially Expressed Gene Analysis
Table 2 displays 94 differentially expressed proteins, of
note few proteins (9) are downregulated, while the major-
ity (85) are up-regulated, as shown in Table 2.
Bioinformatic Analysis
Data represent the differentially expressed regulated pro-
teins were further evaluated to obtain details of biological
processes, cellular functions, networks, and signaling path-
ways related to comorbidities and diseases associated with
T2DM. The dataset was integrated into different software
such as IPA software, and Pathway Studio 9 software for
the analysis of molecular pathways and networks.
Biological Pathways
Canonical Pathway Analysis
The dataset was analyzed using IPA core analysis to achieve
a fundamental profile of the molecular processes underlying
T2DM and its complications. Related canonical pathways
categorized the differentially expressed genes.
Categorization was based on a multiple testing correction
of p-value less than 10−2 of the present dataset to the numbers
of genes of the IPA knowledge data of each pathway.
Figure 1 displays a conical illustration of the top 15 signifi-
cant enriched biological pathways in T2DM patients (see
Supplementary Table S2 for details). The top 5 enriched
signaling pathways in rank were LXR/RXR Activation,
FXR/RXR Activation, Acute Phase Response Signaling,
Table 1 Clinical and Biochemical Data of the Study Subjects
Characteristics Control
(n=55)
T2DM
(n=85)
P
Age (years) 35.69 (11.11) 52.35(9.96) <0.0001
BMI (kg/m2) 29.12 (5.26) 31.28 (5.11) 0.021
Glucose (mM) 4.97 (1.12) 8.67(3.73) <0.0001
HbA1c (%) 5.71 (0.62) 7.56(1.83) <0.0001
eAG (mM) 6.50 9.50 <0.0001
Triglycerides (mM) 1.21 (0.78) 1.66 (1.11) 0.010
TC (mM) 4.60 (0.97) 4.83(2.05) 0.448
HDL (mM) 1.62 (0.37) 1.21 (0.39) 0.055
LDL (mM) 2.72(0.76) 2.82(0.75) 0.424
Albumin (g/L) 45.56(2.63) 45.24(2.78) 0.524
ALT (U/L) 17.11(2.42) 27.22(1.99) 0.002
Total bilirubin (µmol/
l)
7.96 (3.85) 9.32(6.19) 0.128
Total proteins(g/L) 73.17(7.56) 71.49(9.32) 0.294
ALP (U/L) 72.31(31.33) 71.25(23.39) 0.827
Creatinine (µmol/l) 69.02 (15.64) 72.68(23.91) 0.349
CRP (mg/l) 5.63 (2.09) 7.78 (7.11) 0.046
C-peptide (pg/mL) 348.85 (173.79) 243.08
(127.59)
<0.0001
Insulin (pg/mL) 294.88 (75.45) 99.75 (85.29) <0.0001
Notes: Data are presented as means (SD). ANCOVA test was used to analyze,
including age and gender effects. Two tailed p value is significant at <0.05.
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DSB, diastolic
blood pressure; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipo-
protein cholesterol; HDL-C, high-density lipoprotein cholesterol; ALT, alanine
transferase; ALP, alkaline phosphatase; eAG, estimated average glucose; HbA1c,
glycosylated hemoglobin; CRP, c-reactive protein.
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Table 2 T2DM Differentially Expressed Proteins
Metabolite/Protein Name (GenBank ID) Fold Change (T2DM to
Control)
P value
(Gene
Symbol)
Accession
Number
Insulin INS P01308 −1.73 0.025
Matrix metallopeptidase 9 MMP9 P14780 −1.9 0.004
Secreted phosphoprotein 1 SPP1 P10451 −2.66 0.031
Islet amyloid polypeptide IAPP P10997 −2.45 0.002
Apolipoprotein C3 APOC3 P02656 −0.62 0.015
Apolipoprotein H APOH P02749 −1.43 0.024
Apolipoprotein C1 APOC1 P02654 −1.55 0.032
Apolipoprotein A2 APOA2 P02652 −1.65 0.014
Immunoglobulin heavy constant gamma 4 IGHG4 P01861 1.24 0.021
Tumor necrosis factor TNF P01375 1.62 0.006
Intercellular adhesion molecule 1 ICAM1 Q99930 1.75 0.004
Angiotensinogen AGT P01019 2.45 0.001
Coagulation factor II F2 P00734 2.55 0.0001
Kininogen 1 KNG1 P01042 3.16 0.002
Interleukin 6 IL6 P05231 2.44 0.021
Parathyroid hormone PTH P01270 1.92 0.035
Apolipoprotein E APOE P02649 1.85 0.018
Glucagon GCG P01275 2.25 0.009
Gelsolin GSN P06396 1.65 0.016
Chemokine (C-C motif) ligand 2 CCL2 P13500 2.8 0.024
Complement component 5 C5 P01031 1.85 0.031
Leptin LEP P41159 2.51 0.0001
Serpin peptidase inhibitor, clade E, member 1 SERPINE1 P05121 −1.8 0.042
Fibronectin 1 FN1 P02751 1.84 0.025
Vitronectin VTN P04004 1.48 0.035
Apolipoprotein A-IV APOA4 P06727 1.95 0.018
Apolipoprotein A-I APOA1 P02647 2.15 0.029
Transferrin TF P02787 2.24 0.016
Peptide YY PYY P10082 1.48 0.041
Ghrelin/obestatin prepropeptide GHRL Q9UBU3 2.58 0.026
Resistin RETN Q9HD89 1.95 0.013
Paraoxonase 1 PON1 P27169 2.36 0.024
Retinol binding protein 4 RBP4 P02753 3.75 0.001
Titin TTN Q8WZ42 1.82 0.04
Plasminogen PLG P00747 3.85 0.035
Complement component 3 C3 P01024 2.5 0.018
Actin, gamma 1 ACTG1 P63261 1.24 0.027
Transthyretin TTR P02766 2.25 0.011
Ceruloplasmin CP P00450 3.55 0.009
Serpin peptidase inhibitor, clade F, member 1 SERPINF1 P36955 2.08 0.043
Serpin peptidase inhibitor, calde G, member 1 SERPING1 P05155 1.85 0.038
Apolipoprotein C-III APOC3 P02656 2.54 0.027
Serpin peptidase inhibitor, clade C member 1 SERPINC1 P01008 1.69 0.014
Alpha-1-microglobulin/bikunin precursor AMBP P02760 1.25 0.026
Apolipoprotein B APOB P04114 3.21 0.018
Glutamic-pyruvate transaminase GPT P24298 4.21 0.004
Haptoglobin HP P00738 3.24 0.003
Kallikrein B, plasma 1 KLKB1 P03952 3.25 0.01
(Continued)
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Table 2 (Continued).
Metabolite/Protein Name (GenBank ID) Fold Change (T2DM to
Control)
P value
(Gene
Symbol)
Accession
Number
Serpin peptidase inhibitor, clade A, member 6 SERPINA6 P08185 2.75 0.027
Clusterin CLU P10909 2.65 0.042
Melanocortin 2 receptor MC2R Q01718 4.2 0.057
Complement factor B CFB P00751 2.55 0.048
Orosomucoid 1 ORM1 P02763 2.85 0.034
Alpha-2-glycoprotein 1, zinc-binding AZGP1 P25311 3.05 0.017
Alpha-2-HS-glycoprotein AHSG P02765 2.45 0.027
Coagulation factor IX F9 P00740 4.15 0.0001
Serum Amyloid A4 SAA4 P35542 3.4 0.0001
Apolipoprotein A-II APOA2 P02652 2.7 0.020
Serpin peptidase inhibitor, clade F, member 2 SERPINF2 P08697 1.69 0.032
Apolipoprotein A-II APOC2 P02655 1.68 0.014
Keratin 14 KRT14 P02533 3.05 0.007
Serpin peptidase inhibitor, clade A, member 3 SERPINA3 P01011 2.45 0.001
Pro-platelet basic protein PPBP P02775 4.6 0.007
Serpin peptidase inhibitor, clade D, member 1 SERPIND1 P05546 3.51 0.003
Complement component 1, s subcomponent C1S P09871 2.45 0.028
Complement component 4, binding protein, alpha C4BPA P04003 1.85 0.037
Lectin, galactoside-binding, soluble, 3 binding
protein
LGALS3BP Q08380 2.05 0.024
Proteoglycan 4 PRG4 Q92954 1.45 0.036
Histidine-rich glycoprotein HRG P04196 1.65 0.038
Fibulin 1 FBLN1 P23142 1.58 0.044
Lumican LUM P51884 1.95 0.043
Apolipoprotein L, 1 APOL1 O14791 1.25 0.03
Complement component 4B C4B P0C0L5 2.24 0.037
Hemopexin HPX P02790 2.48 0.022
Complement component 1, C1R P00736 1.47 0.041
r subcomponent
Group-specific component Vitamin D Binding
Protein
GC P02774 1.56 0.041
Ficolin FCN3 O75636 2.05 0.035
Inter-alpha inhibitor H3 ITIH3 Q06033 1.84 0.028
Complement component C2 P06681 2.14 0.037
Leucine-rich alpha-2-glycoprotein 1 LRG1 P02750 3.15 0.021
Haptoglobin-related protein HPR P00739 2.85 0.019
Keratin 2 KRT2 P35908 3.48 0.003
Complement factor I CFI P05156 3.24 0.008
Immunoglobulin heavy constant gamma 3 IGHG3 P01860 2.15 0.016
Orosomucoid 2 ORM2 P19652 1.85 0.024
Complement component 6 C6 P13671 1.34 0.037
Afamin AFM P43652 2.15 0.035
Calmodulin-1 CALM1 P0DP23 3.43 0.010
Alpha-1-B glycoprotein A1BG P04217 1.55 0.039
Immunoglobulin kappa constant IGKC P01834 1.65 0.026
Complement component 7 C7 P10643 2.31 0.028
Complement component 9 C9 P02748 2.46 0.031
(Continued)
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Atherosclerosis Signaling, and Clathrin-mediated
Endocytosis, as shown in Table 3.
The Retinoid X Receptors (RXRs) were on top of the
signaling pathways, which includes 31 upregulated genes
and 3 downregulated genes of the 128, as shown in
Supplementary Table S3). RXRs are nuclear receptors
that exert the biological effects of retinoids by the partici-
pation of retinoic acid-mediated gene, which affects bio-
logical functions such as lipid metabolism, molecular
transport, small molecule biochemistry. The second path-
way is The Farnesoid X receptor (FXR), which includes
29 upregulated genes and 3 downregulated genes of the
137 genes of IPA base knowledge (Table S4). FXR is
a member of the nuclear family of receptors and has
a fundamental function in the regulation of numerous
metabolic pathways, such as bile acid metabolism and its
control (Figure 2). The third pathway is the Acute Phase
Response Signaling, whereas 34 DRGs of the dataset were
detected of which one gene is downregulated, and 33 were
upregulated out of the 188 genes of IPA base knowledge
(Table S5). This pathway is a cytokine signaling pathway
where it is activated by tissue injury, trauma, surgery,
cancer, immunologic disorders, and in response to micro-
organisms as a protective pathway. Following that, the
Table 2 (Continued).
Metabolite/Protein Name (GenBank ID) Fold Change (T2DM to
Control)
P value
(Gene
Symbol)
Accession
Number
Complement component 1, q subcomponent,
C chain
C1QC P02747 2.81 0.033
Complement component 8, alpha polypeptide C8A P07357 1.89 0.029
Notes: Data displays the list of the 94 metabolites that were identified in the ResNet Mammalian database with their corresponding GenBank ID. Data represent the
differentially expressed regulated proteins with fold changes and p values in T2DM compared to control subjects.
Figure 1 Displays a conical illustration of the top 15 significant enriched pathway analysis in the proteomic and metabolomic dataset, which are differentially expressed genes
in T2DM. Data are presented as bars based on the -log of P values and the ratio indicates the percentage of DRGs of the study compared to the IPA knowledge base.
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next fourth pathway is the Atherosclerosis Signaling,
whereas 20 DRGs of the data set were detected, of
which two were downregulated, and 18 were upregulated
of the 127 genes of IPA base knowledge (Table S6). This
pathway is a specific form of a chronic inflammatory
process that functions as a cell to cell signaling and
interactions and cellular movement in the cardiovascular
system. The next pathway is Clathrin-mediated
Endocytosis Signaling, whereas 19 DRGs of the data set
were detected, of which 2 genes were downregulated, and
17 were upregulated out of the 196 genes of IPA base
knowledge shown in (Table S7). Clathrin-mediated
Figure 2 Role of the farnesoid X receptor (FXR) and bile acids. Network displays DRGs, which are upregulated (red) and downregulated (green) genes. The figure shows
the role of these DRGs in activation (A), expression (E), correlation (CO), localization (LO), phosphorylation (P), transcription (T), translocation (TR), regulatory binding
(RB), inhibition (I), and molecular cleavage (M), which induces the nuclear farnesoid X receptor (FXR) or NR1H4 (nuclear receptor subfamily 1, group H, member 4) with its
effect on the suppression of cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting enzymes of bile acid synthesis from cholesterol.
Abbreviation: CP, canonical pathway.
Table 3 Top Five Canonical Pathways of DRGs of the Diabetic Subjects with Their p-values (Based on Core Analysis in Ingenuity
Pathway Analysis [IPA])
Top Canonical Pathways Downregulated
Genes
Upregulated
Genes
Name p-value Overlap
LXR/RXR activation 2.12E-55 26.6% 3/128 (2%) 31/128 (24%)
FXR/RXR activation 5.24E-50 23.4% 3/137 (2%) 29/137 (21%)
Acute phase response signaling 1.12E-49 18.8% 1/181 (1%) 33/181 (18%)
Atherosclerosis signaling 2.09E-27 15.7% 2/127 (2%) 18/127 (14%)
Clathrin-mediated endocytosis signaling 6.83E-22 9.7% 2/196 (1%) 17/196 (9%)
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Endocytosis Signaling is involved in endocytosis, which is
the principal pathway for the movement of nutrients, hor-
mones, and other signaling molecules from the extracellu-
lar into intracellular structures across the plasma
membrane. Other canonical biological pathways were IL-
12 Signaling and Production in Macrophages pathway,
whereas 16 DEGs of the dataset were detected of which
one gene was downregulated, and 15 were upregulated of
the 136 genes of the IPA base knowledge (Table S2). IL-
12 is produced primarily by dendritic cells, macrophages,
and monocytes, and affecting Th1 immune response and
Th17 cells activation. Following that, the Production of
Nitric Oxide and Reactive Oxygen Species in
Macrophages, whereas 16 DEGs of the data set were
detected of which one gene is downregulated, and 15
were upregulated of the 194 genes of IPA base knowledge
as shown (Table S2). This pathway is central to the control
of infection by microbes.
Diseases Associated with DRGs
Using IPA base knowledge, we detected several significant
diseases associated with the present dataset of the
current study (Table S8 and S9). The top five affected
diseases in rank based on higher p values for multiple
testing for corrections were presented in Table 4. These
disorders are Neurologic Diseases, the Organismal Injury,
and Abnormalities, the Psychological Disorders, the
Inflammatory Response Disorders, and Metabolic Disorders.
Further, we analyze the top significant disorders associated
with each category of these diseases, as shown in Table 5.
Neurologic and Psychological Diseases
Category
Among this category, progressive neurological disorders
included 3 DRGs of the data set of which APOE and
SERPING1 are upregulated, and INS is downregulated,
which increases the prediction of the progressive neurolo-
gical disorders, as shown in Table 5. Dementia is
a neurological and psychological disorder that included 2
DRGs of the data set, whereas APOE is upregulated, and
the INS is downregulated, which increases the prediction
of the prediction to dementia, as shown in Table 5.
Alzheimer’s disease is a neurological and psychological
disorder that included 2 DRGs of the data set, whereas
APOE is upregulated, and the INS is downregulated,
which increases the prediction of the prediction to
Alzheimer’s diseases as shown in Table 5. Eating disorder
is a significant psychological problem in diabetic subjects.
As displayed in Table 5. The eating disorder is predicted to
increase with six DRGs, which are LEP, IL6, GCG,
SERPINE1, TNF, and INS.
Organismal Injury and Abnormalities
Category
Amyloidosis, is one of the Organismal Injury and
Abnormalities. As displayed in Table 5, INS, IL6 increases
while APOE and APOA1 decrease the prediction of
amyloidosis.
Apoptosis of the endothelial cells is one of the
Organismal Injury and Abnormalities predicted to be
increased with (z-score 3.29). As presented in Table 5, the
apoptosis of the endothelial cells is predicted to increase with
12 genes of DRGs, which are PLG, RBP4, KNG1, LEP,
SERPINA3, AGT, SERPINE1, LUM, SERPINC1, TNF,
and SPP1.
The damage of the genitourinary system is predicted to
be increased with (z-score 2.203). As displayed in Table 5,
the damage of the genitourinary system is predicted to
increase with seven DRGs, which are CFB, AGT, IL6,
C4A/C4B, ICAM1, TNF, and GC.
Inflammatory Response Disorders
Category
Degranulation of cells is predicted to be increased with active
z-score 2.60. As displayed in Table 5, the degranulation of
cells is predicted to increase with seven genes, which are
PPBP, CCL2, F2, LEP,GCG,C4A/C4B, andTNF. (Figure S1)
Activation of leukocytes is predicted to be increased
with active z-score 2.359. As displayed in Table 5, the
activation of leukocytes is predicted to increase with 17
genes of DRGs, which are RBP4, KLKB1, KNG1, CCL2,
F2, LEP, AGT, IL6, APOA1, IGHG3, ATP, SERPINF1,
FN1, ICAM1, TNF, GC, and VTN.
Table 4 Top Five Diseases and Disorders of the DRGs of the
Present Study with Their p-values (Based on Core Analysis in
Ingenuity Pathway Analysis [IPA])
Diseases and Disorders p-Value Range # Molecules
Name
Neurological disease 2.13E-09–2.44E-30 63
Organismal injury and abnormalities 1.19E-08–2.44E-30 89
Psychological disorders 1.01E-08–2.44E-30 49
Inflammatory response 1.20E-08–8.76E-29 76
Metabolic disease 3.88E-09–2.13E-28 60
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Metabolic Disorders Category
Hypertriglyceridemia is on the top of the metabolic disorders
and cardiovascular diseases (CVD) associated with T2DM,
with Z-score of 2.035. Hypertriglyceridemia is predicted to
increase with the following upregulated genes APOA2,
APOB, APOC3, APOE, IL6, SERPINF1, TNF, and the down-
regulated gene INS as shown in Table 5.
Dyslipidemia is ametabolic disorder commonly associated
with T2DMwith a Z-score of 1.260. Dyslipidemia s predicted
to increase with the following genes APOA2, APOB, APOC3,
IL6, INS, and TNF, as shown in Table 5. See Supplementary
figures (Figures S1).
Functional Disorders Associated with
Dataset in T2DM
Furthermore, we analyzed the common functional disor-
ders which are associated with DRGs of that set using IPA
base knowledge. The top 5 functions affected are Cellular
compromise, Protein synthesis, Molecular transport, Lipid
metabolism, and Small molecule biochemistry. Table 6
Illustrates the genes associated with the top functions.
Further, we explore the top five functions in each category
associated with T2DM and identify the genes of the DRGs of
the data set per each function, as shown in Table 7. The most
affected function in the cellular component category is the
degranulation of cells (Table 7) and (Figure S1), of which
seven genes are PPBP, CCL2, F2, LEP, GCG, C4A/C4B,
TNF increased the prediction of the degranulation. Fat Acid
Metabolism under the lipid metabolism category with activa-
tion Z-score of 3.62, including 19 genes of the data set
increased the prediction of FA metabolism (Figure S2a),
Protein synthesis under Protein Metabolism category with
a P value of 7.74E-24, Z-score of 2.88, with 19 DRGs of the
data set to increase the prediction of protein synthesis (Figure
S2b). The release of lipids (p=2.11E-12), Z-scores of 3.70
having 15 DRGs which increase the prediction of the release
of lipids, and release of Ca+2, P=1.15E-11 and Z-scores of 2.75
having 11 DRGs of the data set which increased the prediction
of the release of Ca+2, (Figure S2c), and quantity of metal ions
(p=1.61E-20), Z-scores of 3.16 having 10DRGswhich increase
the prediction of the quantity of metal ions (Figure 3) under
Molecular transport category. All molecules involved in func-
tions are illustrated in supplementary (Table S10) for details.
We explore some specific disorders associated with organ
injuries. Data obtained from the current analysis showed that
Table 6 Top Five Functions of the DRGs of the Present Study
with Their p-values (Based on Core Analysis in Ingenuity Pathway
Analysis [IPA])
Molecular and Cellular Functions
Category of Function p-value Range # Molecules/Function
Cellular compromise 2.50E−09–8.76E-29 42
Protein synthesis 1.64E-12–2.30E-25 46
Molecular transport 1.08E−08–6.29E-25 59
Lipid metabolism 9.51E−09–1.51E-24 55
Small molecule biochemistry 1.08E−08–1.51E-24 58
Table 5 Top Disease Category with Examples of Each of the Present Study with Their p-values and DRGs Involved (Based on Core
Analysis in Ingenuity Pathway Analysis [IPA])
Disease Category/Example p-value Genes in Dataset
Neurologic and psychological diseases
Progressive neurological disorders 8.17E-28 APOE, SERPING1, INS
Dementia 2.44E-30 APOE, INS
Alzheimer’s diseases 6.154E-28 APOE, INS
Eating disorder 1.01 E-8 LEP, IL6, GCG, SERPINE1, TNF, INS
Organismal injury and abnormalities
Amyloidosis 2.13E-28 INS, IL6 APOE APOA1
Apoptosis of the endothelial cells 3.51E-11 RBP4, KLKB1, KNG1, CCL2, F2, LEP, AGT, IL6, APOA1, IGHG3, ATP, SERPINF1, FN1, ICAM1, TNF, GC, VTN
Damage of the genitourinary system 1.243E-15 CFB, AGT,IL6, C4A/C4B, ICAM1, TNF GC.
Inflammatory response
Degranulation of cells 5.06 E-24 PPBP, CCL2, F2, LEP, GCG, C4A/C4B, TNF
Activation of leukocytes 2.63 E-15 RBP4, KLKB1, KNG1, CCL2, F2, LEP, AGT, IL6, APOA1, IGHG3, ATP, SERPINF1, FN1, ICAM1, TNF, GC, VTN.
Metabolic disorders
Hypertriglyceridemia 3.60 E-13 APOA2, APOB, APOC3, APOE, IL6, SERPINF1, TNF,INS
Note: Genes in the data set are predicted to be involved based on measurement.
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7 genes out of 16 which are CFB, AGT, IL-6, C4B, ICAM1,
TNF, GC are increased, while HPX gene is decreasing, which
have measurements consistent with predictive increases in
damage of kidney with Z-score of 2.20, and a P value of
8.19E-15 (Figure 4A and B).
Regulation of the Dysregulated Gene
Expressions of the Data Set and Their
Impact on Biological Functions and
Diseases
Upstream Regulator Analysis of the Transcription
Regulators and Kinases Factors
Further, we used the IPA upstream regulator analysis
that would explain the changes in gene expression as
downstream targets. The aim is to understand the under-
line regulation of the expression changes seen in the
dataset of T2DM. Transcription factors are proteins
that control the rate of RNA transcription to regulate
the gene expression (up and down) based on the cell
state and organ activity to help in cell homeostasis. The
five most significant upstream transcript regulators
based on Z score in the ranking were, Signal transducer
and activator of transcription 3 (STAT3) as shown in
Figure 5, Signal transducer and activator of transcription
1 (STAT1), Hypoxia-inducible factor 1-Alpha (HIF1A),
followed by CCAAT/enhancer-binding protein alpha
(CEBPA), followed by CCAAT/enhancer-binding pro-
tein beta (CEBPB) is presented in Table 8, and dis-
played in Supplementary figures (S3).
Further, we observed the top 5 activated kinases,
which are ATM, JAK2, JAK1, MTOR, and AKT1, as
upstream regulators that affect the expression of some
genes of the data set as shown in Table 9, and supple-
mentary Figure S4.
Top Regulator Effects
Moreover, we look for the master regulator of proteins of
the dataset, which regulate other proteins using IPA stream
analysis. Also, this analysis identifies potential mechan-
isms linked with phenotype changes such as disease or
functional disorders and explain the biological role of the
upstream regulator, via its regulation on a gene or sets of
genes. Table 10 illustrates the top three regulator proteins
which regulate other proteins of the dataset. Among the
top downregulated proteins of the dataset are, INS targets
10 molecules (Figure 6A), and SPP1 targets 9 of DEG
(Figure S5a), while among the upregulated proteins are
TNF targets 32, IL6 targets 29 (Figure 6B), LEP targets
19, AGT targets 14, and APOE targets 13 molecules of the
data set (Table S11), and (Figure S5b)
Mechanistic Networks of Top Regulators
Further, in order to understand the mechanistic pathway by
which a single protein affects a downstream target protein
of the data set, we did the mechanistic analysis. For exam-
ple, insulin is the primary hormone underlying the patho-
genesis of T2DM and its comorbidities, which targets TNF,
AGT, APOA1, GCG, GHRL, ICAM1, IGKC, IL6, and LEP.
It was interesting to investigate the interaction of INS with
some of the upregulated target proteins of interest such as
TNF, IL6, and LEP, which regulate other proteins to under-
stand the mechanistic of their interactions and crosstalk
among a dataset of T2DM. INS upregulates LEP expression
directly or indirectly through intermediates such as
D-glucose, POMC, PI3 complex, which in turn affects
transcription factors such as FOXO1, STAT3, SIRT1, EP
300, and via effects on ligand-dependent nuclear receptor
such as PPARG, and NR3C1 (Figure S6). INS upregulates
TNF gene expression directly or indirectly through inter-
mediates such as D-glucose, SIRT1, EP 300, FOS, POMC,
Table 7 Top Five Functions of Each Category of the Present Study with Their p-values (Based on Core Analysis in Ingenuity Pathway
Analysis [IPA])
Top Molecular and Cellular Function per Each Category
Molecular and Cellular Category/Top Function Example p-value z-Score # Molecules
Cellular compromise/degranulation of cells 5.06 E-24 2.60 42
Protein synthesis/protein metabolism 7.74E-24 2.88 43
Molecular transport/release of lipids
Molecular transport/quantity of Ca+2
2.11E-12
2.25E-20
3.70
3.31
15
27
Lipid metabolism/fat acid metabolism 9.71E-22 3.62 32
Small molecule biochemistry/release of Ca+2 1.15E-11 2.75 14
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PI3 complex which in turn affects the transcription factors
such as FOXO1, FOXO3, REL, STAT3, and via effects on
ligand-dependent nuclear receptor such as PPARG, and
NR3C1 and via the effect on lipid metabolism which acts
directly or via c-JUN (Ap1) kinase (Figure S6). In similar
basis, INS upregulates IL6 expression directly or indirectly
(Figure 7A) through intermediates such as D-glucose,
SIRT1, EP 300, FOS, POMC PI3 complex which in turn
affects transcription factors such as FOXO1, FOXO3, REL,
STAT3, and via effects on ligand-dependent nuclear recep-
tor such as PPARG, and NR3C1 and via the effect on lipid
which acts directly or via c-JUN (Ap1) kinase. The mechan-
ical network analysis demonstrated two upregulated protein
of the dataset., LEP targets 16 genes directly, and 28 genes
indirectly of the data set via 21 possible mechanistic reg-
ulations (Figure S6), and IL6 targets 29 genes directly and
34 genes (Figure 7B) indirectly of the data set via 23
mechanistic regulators, TNF targets 32 genes directly, and
27 genes (Figure 7C) indirectly of the data set via 21
mechanistic regulators and one of the downregulated pro-
tein is INS which targets 10 genes directly and 34 genes
indirectly via 20 mechanisms of mechanistic regulations.
The protein-protein interaction involves many hubs
such as kinase, ligand-dependent nuclear receptor, tran-
scription factor regulators, endogenous chemical,
enzymes, and growth factors. As displayed in
Figure (7B and C) for IL6 and TNF as the primary
triggers of other proteins of the data set of T2DM.
Such mechanistic interaction of proteins could explain
the actions of such DRGs in diabetes and how it can
modify insulin action on metabolic, cellular,
and biological process/and disorders. (see supplement
Figures S7a-d) and its uses as biomarkers in athero-
sclerosis and hypertension (Figure 8)
Figure 3 Molecular transport category. Displays DRGs, which are upregulated (red) and downregulated (green) genes involved in molecular transport, quantity of metal ions. Brown
arrow, increase prediction; yellow arrow, decreased prediction; and gray arrow, no known predicted effects. RPBP, KNG1, ORM1, CCL2, GHRL, F2, APOC3, AGT, GCG, TTR, PTH,
APOE, NAD, ATP, FN1, ICAM1, INS, PYY, and TNF, increase prediction of quantity of metal ions. GCN, SPP1, IAPP, phosphate as IL6 decrease prediction of quantity of metal ions.
Abbreviation: C, causative relationship.
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Network Analysis
We investigated the interactions among the DRGs, path-
ways, regulators, and other molecules in type 2 diabetics
and identified 12 eligible networks associated with various
biologic processes, functions, and diseases-as displayed in
a table (Table S12).
Figure 4 Renal diseases. (A) Networks display DEGs which is upregulated (red) and downregulated (green) genes involved in damage of kidney in T2DM based on the
multiple corrections of the log P value. The deep orange arrow indicates the prediction of an increase of activation, yellow arrow indicates a decreased prediction of
activation, and grey arrow could affect. IL6, ICAM1, GC, CFB, C4A/C4B, AGT, and TNF increase the prediction of kidney damage. (C), Causative and (CO), correlation
relationships. (B) Network displays the role of acute inflammatory response pathway and cascade involving TNF and IL6 as an upstream regulator which affects the upstream
transcription regulators; NFKB and NF-IL6 and kinases such as c-jun, and c-fos, which affects downstream targets related to damage of kidneys such as IL6, ICAM1, GC,
CFB, C4A/C4B, AGT, and TNF which increase prediction of kidney damage.
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Network 1 included the top functions and diseases, which
are Cellular Compromise, Inflammatory Response, and
Neurological Disease, which comprise 16 DRGs. At the
same time, the transcription factor NFKB complex is a hub
for acute phase response signaling, cell functions such as
degranulation, inflammatory response, and dementia as an
example of a neurological disorder, as shown in (Figure 9A).
Network 2 displays the top functions and diseases which are
Lipid Metabolism, Molecular Transport, Small Molecule
Biochemistry which comprise 14 DRGs; Apolipoproteins
(APOC1, APOC2, APOC3, APOA2, APOA4) which are
connected to the hubs of nuclear complexes NCOR-LXR-
Oxysterol-RXR-9 cis linked to retinoid signaling activation,
and FXR-ligand FXR-Retinoic linked to FXR-RXR activation
and bile acid metabolism. The networks display proteins
involved in blood hemostasis and coagulation such as F9,
KLKB1, SERPINC1, HPX1, which crosstalk with each other
and connected to Apolipoproteins via PON1. ERK1/2, which
are extracellular signal-regulated kinases, acts as a hub, which
is regulated by RBR4, RETN, and HPX, as shown in
(Figure 9B).Network 3 displays the top functions and diseases,
which are Developmental Disorder, Humoral Immune
Response, Inflammatory Response, which comprise 13
DRGs. The network display two canonical pathways; the
acute phase response signaling, which includes AFM, TNF,
CFB, CRB, SERPING1, and CIS, and hub of NFKB family.
The other crucial canonical pathway (CP) is the complement
pathway, which includes genes such as CF1, CRB,
SERPING1, CIS1, CIR, CFB, and complete component1 as
a hub. The network displays the extensive crosstalk of TNF,
SERPING1, and complement in network 3. Moreover, the
figure display molecules involved in two crucial disorders
associated with this network in T2DM, which are immunode-
ficiency and rheumatoid diseases (RD). In RD, many mole-
cules are involved, such as complete component1, FCN, TNF,
CFB, C1Q, and C1Q, as shown in Figure 9C. Network 4
displays the associated top functions and diseases, which are
Cell-To-Cell Signaling and Interaction, Cellular Movement,
Inflammatory Response, which comprise 9 DRGs. The top 3
CP are Hepatic Fibrosis, Atherosclerosis signaling, and GP6
signaling pathway. The immune response of macrophage as
cell-to-cell signaling disorders involves 3 DRGs, which are
IL6, LUM,VTN, the cellularmovement disorders include IL6,
VTN, and connective tissue disorders include collagen type11,
IL6, LUM, PLG, and PRG4. Moreover, severe injury such as
Figure 5 Upstream regulators-TF. Networks display target genes that are upregu-
lated (red) and downregulated (green) genes in response to the top activated
transcription factors as an upstream regulator in the data set of T2DM. Signal
transducer and activator of transcription 3 (STAT3), relations in arrows are expres-
sion (E), protein–DNA interaction (PD), phosphorylation (P), and transcription (T).
Arrows: brown, increase expression; golden arrow and dotted arrow, decreased;
and grey, not predicted effect. Expression of HP, CCL2, LEP, SERPINA3, AGT,
AHSG, ATP, APO4, SERPINE1, and ICAM1 is activated. The expression of MMP is
inhibited. Others are affected but not predicted.
Table 8 Top Five Upstream Regulator Transcription Factors Affecting the Expression of the Genes of the Data Set of the Present
Study with Their p-values, Z-Score, and Target Molecule (Based on Core Analysis in Ingenuity Pathway Analysis [IPA])
Name Predicted
Activation
State
Activation
z-Score
p-value
of
Overlap
Target Molecules # of molecules Activated of the Data
Set
STAT3 Activated 2.569 1.28E−08 AGT,AHSG,APOA4, ATP,CCL2, CFB,FN1, HP,ICAM1, IL6 10(15)
STAT1 Activated 2.521 1.28E-11 AGT,APOC2, APOE,C1R,C1S,C4A/C4B,CCL2, CFB,
ICAM1, IL6
9 (15)
HIF1A Activated 2.771 1.54E−07 AGT,APOE,ATP,FN1, HP,IL6, KRT14,LEP,MMP9,SERPINE1 9 (12)
CEBPA Activated 2.046 3.12E-10 AGT,APOA4,APOB,APOC3,F9,HP,HPR,ICAM1,IL6,KRT14 9 (15)
CEBPB Activated 2.288 3.85E-16 AGT,APOB,APOC3,CCL2,CP,FBLN1,HP,HPX,ICAM1,
IGKC
11(20)
Note: Data represent active downstream target genes out of all downstream genes in parenthesis.
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cardiac hypertrophy is displayed, which indicates the involve-
ment of several DRGs of IL6, LUM, LRG1, PLG, with other
molecules such as Alpha actinin, PDGF, Tgf beta, and TLR2
and TLR4. These toxic injuries of liver, heart, and kidney are
severe complications in long-term and uncontrolled T2DM, as
shown in Figure 9D. Other networks are involved in different
diseases and functions related to T2DM and its comorbidities
such as Cancer, Cardiovascular Disease, Organismal Injury,
and Abnormalities (network 5).
Discussion
The pathogenesis of T2DM and its associated comorbidities is
presently challenging to identify specific biomarkers and
pathways involved in its complications. Diabetes is a chronic
polygenic disorder resulted from several biological processes
that interact in a dense network, rather than from an abnorm-
ality of a single effector gene product. Since the biological
functions are the results of molecular interactions, the func-
tional annotations of differentially expressed genes should
include the effect of many genes on different pathways and
their interactions on the different biologic processes and net-
works that have a potential impact on T2DM. Understanding
the biological pathways and their network information is use-
ful in predicting the risk and understanding the progress of the
disease using the integration of proteomics and metabolic
dataset.
In the current study, IPA software was used to integrate the
fold expression of DRGs for the development of molecular
pathways and networks in T2DM. As illustrated in this study,
the data explore significant pathways in T2DM subjects com-
pared to control subjects to gain more understandings of the
pathogenesis towards diabetic complications. This study iden-
tified differentially dysregulated genes as potential prognostic
biomarkers involved in critical biological processes and path-
ways of proteins that are allied with T2DM comorbidities. The
most important findings of this study are the identification of
the upstream regulators which affect the gene expression such
as transcription factors STAT3, STAT1, and HIF1A, cytoplas-
mic kinases such as JAK kinases and highlight their mechan-
istic actions that affect the expression. Furthermore, the
findings of the present study identified the most commonly
expressed genes: Tumor Necrosis Factor, TNF, Interleukin 6;
IL6, Leptin; LEP, Angiotensinogen; AGT, Apolipoprotein E;
APOE,Coagulation Factor II, Thrombin; F2, Secreted
Phosphoprotein 1; SPP1,Resistin; RETN, and Insulin; INS
that could be used as potential prognostic biomarkers. The
data recognized that IL6 is the top regulator of the DRGs,
followed by LEP. The study identified several networks
which explore the dysregulation of several functions, including
Table 9 Top Five Upstream Kinase Factors Affecting the Expression of the Genes of the Data Set of the Present Study with their p-
values, Z-Score, Target Molecule and Numbers of Mechanistic Works. (Based on Core Analysis in Ingenuity Pathway Analysis [IPA])
Upstream
Regulator
Predicted
Activation State
Activation
z-Score
p-value of
Overlap
Target Molecules in Dataset Mechanistic
Network
ATM Activated 2.607 2.16E−08 CLU, L6, LEP, NAD+, NADP, SERPINE1 (7) 40 (21)
JAK2 Activated 2.211 3.64E−04 CCL2, ICAM1, IL6, TF, TNF (5) 33 (19)
JAK1 Activated 2.189 8.77E−06 CCL2, ICAM1, LRG1, TF, TNF (5) 49 (24)
MTOR Activated 2.187 2.86E−03 CCL2, FN1, IL6, LEP, MMP9, TNF (6) 54 (22)
AKT1 Activated 2.070 1.39E-11 APOC3,ATP,C1QC,CCL2,CLU,FN1,IL6,
LEP,MMP9,PLG(14)
56 (23)
Note: Data in brackets represent numbers of direct mechanistic network affecting gene expression out of all networks (direct and indirect).
Table 10 Top Regulator Proteins That Affect the Expression of
Several Proteins of the Data Set of the Present Study with Their
p-values, Z-Score, and Target Molecule (Based on Core Analysis
in Ingenuity Pathway Analysis [IPA])
Top
Regulator
Activation
z-Score
p-value
of
Overlap
Target Molecules in
Dataset
INS 0.967 2.15E−09 AGT,APOA1,ATP,GCG,
GHRL,ICAM1,IGKC,IL6,
LEP,TNF
LEP 2.185 8.71E-14 APOA1,APOA2,APOA4,
APOH,CCL2,GHRL,HPX,
ICAM1,IL6,INS,ORM1,
phosphate,RETN,
SERPINE1,SPP1,TN
IL6 3.175 1.81E-20 AGT,APOA1,APOB,
APOE,ATP,CCL2,CLU,CP,
FN1,GCG,HP,HPX,
ICAM1,KRT14,LEP,LRG1,
MMP9,ORM1,PLG,PON1,
PPBP,SAA4,SERPINA3,
SERPINE1,SPP1,TF,TTR
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cell components, and molecular transport process associated
with inflammatory responses that modify the insulin pathway.
Top comorbidities and complications associated with DRGs
are neurological and psychological disorders, organ injuries
related disorders such as renal damage, and connective tissue
disorders, and acute inflammatory disorders.
In this study, we identified 94 genes that were differen-
tially dysregulated in Arab subjects with T2DM compared to
healthy, non-diabetic controls. In order to explore the
mechanisms causing changes in gene expression, we identi-
fied upstream regulators in order to provide biological insight
into the observed expression changes. The essential top
upstream regulator identified was IL6 of the data set, fol-
lowed by transcription factors and kinases. IL6 is the master
of all regulators, which controls 63 genes of the dataset, and it
exerts its effects on the observed gene expression via 23
regulatory mechanisms with activation of Z-score (3.175).
IL6 interacting directly on PI3 (Peptidase Inhibitor 3) com-
plex, P38MAPK (stress signaler p38 mitogen-activated pro-
tein kinase), AKT (Serine/Threonine Kinase), and affects
TNF gene expression and also through other regulatory
molecules such as STAT3 (Signal Transducer And
Figure 6 Top regulator effects (A) Regulator effects of the top downregulated proteins
(INS) on target proteins of the dataset. Target genes that are upregulated (red) and
downregulated (green) genes. INS activates the expression of LEP, IL6, GCG, APOA1,
IGKC, and TNF. INS inhibits expression of GHRL, AGT, ATP, and ICAM1. Brown,
increased and golden arrow, decreased. Relations in arrows are expression (E), phos-
phorylation (P), and transcription (T). (B) Regulator effects of the top upregulated
protein (IL6) on target proteins of the dataset. Target genes that are upregulated (red)
and downregulated (green) genes. brown arrow: increase expression; golden arrow:
decreased; and grey: not predicted effect. See Supplementary tables. Relations in arrows
are expression (E), phosphorylation (P), and transcription (T).
Figure 7 Mechanistic networks-protein interaction. (A) Networks display interac-
tions of INS with some of the main target proteins of interest, such as IL6. The
pointed arrowheads represent activating relationships, and blunt arrowheads repre-
sent inhibitory relationships. Trigger gene: INS; Upstream regulators: TFs; Target
genes: IL6. (B) Network display interactions of IL6 with some of the main target
proteins of interest such as INS, AGT, LEP, SPP1. The pointed arrowheads represent
activating relationships, and blunt arrowheads represent inhibitory relationships.
(C) Display interactions of TNF with some of the main target proteins of interest
such as INS, IL6, LEP, and SPP1. Trigger gene: TNF; Upstream regulators: kinases
and ligand nuclear receptors; Target genes: INS,IL6, LEP, and SPP1.
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Activator Of Transcription 3), NFKBIB (NF-kappa-B inhi-
bitor beta), and FOXO1 (forkhead box O1), (Figures 6
and 7B). The set of 23 regulators in total connects to the 63-
dataset gene. IL6 is a growth factor with cytokine activity and
protein binding. Interleukin 6 (IL-6), a multifunctional cyto-
kine and has been linked to the pathogenesis of T2DM.17
Increasing the level of circulating IL-6 is a predictor biomar-
ker of T2DM, especially in obese subjects and could be
involved in the development of inflammation and insulin
resistance.18
Furthermore, IL6 downregulates the expression of the
insulin gene, which contributes to the pathogenesis of
T2DM and its related comorbidities. IL6 is participating
in numerous biological processes such as acute inflamma-
tory response as one of the top canonical pathways asso-
ciated with inflammatory response disease such as
activation of leukocytes and degranulation of the cells,
injury of different organs such as renal damage, connective
tissue disorders such as rheumatoid arthritis. It also affects
many molecular functions, such as fat and protein meta-
bolism. The complex signal transduction mechanism of
IL-6/STAT3 may explicate the widespread effects of the
IL6 as a cytokine.19 Monitoring of IL6 in T2DM is of
clinical significance as it is involved in many related
complications such as atherosclerosis (Figure 8), hyperten-
sion (Figure 8), renal damage (Figure 4), metabolic,
inflammatory disorders, and organs and tissues damage
(Table 5).
Moreover, we detected several transcription factors (TF) as
upstream regulators including Signal transducer and activator
of transcription 3 (STAT3), Signal transducer and activator of
transcription 1 (STAT1), Hypoxia-inducible factor 1-Alpha
(HIF1A), CCAAT/enhancer-binding protein alpha (CEBPA),
and CCAAT/enhancer-binding protein beta (CEBPB). Signal
transducer and activator of transcription 3 is one of STAT
family, known as acute-phase response factor, which regulates
downstream target molecule such as; IL6, LEP, JAK2 (Janus
Kinase 2), LIF (LIF Interleukin 6 Family Cytokine), IL10
(Interleukin 10), EGF (Epidermal Growth Factor), SRC
(Proto-Oncogene, Non-Receptor Tyrosine Kinase), IL21
(Interleukin 21), SOCS3 (Suppressor Of Cytokine
Signaling 3), JAK (Janus Kinase), IL6ST (Interleukin 6
Signal Transducer), and binds with other TFs such as EGFR
(Epidermal Growth Factor Receptor), STAT1, JAK2 (Janus
Kinase2), FOS (Fos Proto-Oncogene, AP-1 Transcription
Factor Subunit), PIAS3 (Protein Inhibitor Of Activated
STAT 3), IL6ST, SRC, EP300 (E1A Binding Protein P300),
JUN (Jun Proto-Oncogene, AP-1 Transcription Factor
Subunit), RELA (RELA Proto-Oncogene, NF-KB Subunit),
JAK1, CDKN1A (Cyclin-Dependent Kinase Inhibitor 1A),
HIF1A, STAT2. STAT3 is regulated by BCL2L1 (protein
phosphatase 1, regulatory subunit 52), MYC (MYC proto-
oncogene,), SOCS3, VEGFA (Vascular Endothelial Growth
Factor A), IL6, CCND1 (Cyclin D1), STAT3, VEGF
(Vascular Endothelial Growth Factor F), IL21, BIRC5
(Baculoviral IAP Repeat Containing 5), and HIF1A, which
Figure 8 Network display utility of DRGs as predictive biomarkers for two comorbidities associated with T2DM: atherosclerosis and hypertension. APOA1 and IL6 as
diagnostic for atherosclerosis, and CCL2, TNF, LEP, ICAM1, IL6, INS, SERPINE1, and RETN as efficacy biomarker for treatment. For hypertension, TNF and IL6 for diagnosis
and CCL2, LEP, TNF, ICAM1, and IL6 as efficacy biomarkers for treatment.
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indicates its pleiotropic cellular effects such as expression,
proliferation, apoptosis, growth, differentiation, andmigration.
In the current study, STAT3 regulates the expression of AGT,
AHSG (Alpha 2-HS Glycoprotein), APOA4 (Apolipoprotein
A4), ATP, CCL2 (C-C Motif Chemokine Ligand 2), CFB
(Complement Factor B), FN1 (Fibronectin 1), HP
(Haptoglobin), ICAM1 (Intercellular Adhesion Molecule 1),
and IL6 (Table 8, Figure 5). The current findings of the role of
STA3, and STAT1 as TFs, indicates its significant role in
acute-phase response and inflammation, which is a hallmark
of the biological process and related disorders associated with
comorbidities of T2DMsuch as the damage of kidneywhich is
enriched in the dataset. Previous studies indicated the role of
STAT 3 protein in insulin resistance and diabetes and related
disorders such as damage of kidney, degranulation of cells,
and apoptosis of endothelial cells in microangiopathy.20 Such
exploration of the role of the transcription factors and its
downstream target genes could explain the numerous compli-
cations associated with T2DM.
Further, as upstream regulators that affect the gene
expression of the dataset, we identified several kinases
(Table 9, Figure S4), which can target several genes of
the data set. AKT (Protein kinase B, PKB) is one of 3
closely related serine/threonine-protein kinases (AKT1,
Akt2, and AKT3), which regulates metabolism, prolifera-
tion, cell growth, and angiogenesis.21 The dataset of the
present study showed that AKT is regulated by insulin,
EGF (Epidermal Growth Factor), PDGF (Platelet-Derived
Growth Factor complex), TNF, and IGFI (Insulin-Like
Growth Factor 1), and it regulates downstream several
Figure 9 (A–D) Biological networks. The top four networks are showing interactions between dysregulated genes, functions, diseases, and upstream regulators in T2DM.
Details are displayed in each figure. (A) NW1: The network displays cellular components, inflammatory responses, and neurological diseases. The network displays the
canonical pathway and cellular components regulated by the DRGs. The upregulated (red) and downregulated (green) associated with dementia as a neurological
complication of T2DM. (B) NW2: The network displays lipid metabolism, molecular transport, and small molecular biochemistry. The network displays the cellular
functions and process (fatty acid metabolism, efflux of cholesterol) and inflammatory responses (IR) regulated by the DRGs. The upregulated (red) and downregulated
(green) associated with dyslipidemia and glucose metabolic disorders and Alzheimer’s as neurological complications of T2DM. (C) NW3: The network displays develop-
mental disorders, humoral immune response, and inflammatory responses. The network displays the canonical pathway and cellular process regulated by the DRGs. The
upregulated (red) and downregulated (green) associated with immunodeficiency and rheumatoid arthritis as connective tissue disorders as a complication of T2DM. (D)
NW4: The network displays cell to cell signaling and interaction cellular movements and inflammatory responses. The network displays the canonical pathway and cellular
process regulated by the DRGs. The upregulated (red) and downregulated (green) associated with severe renal, hepatic, and cardiac injuries as complication of T2DM.
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TFs such as GS3 B (Glutamine synthetase root isozyme
B), NOS3 (Nitric Oxide Synthase 3), FOXO1 (Forkhead
Box O1), mTOR (Mechanistic Target Of Rapamycin
Kinase), and NFKB (Nuclear Factor Kappa B). It affects
glucose metabolism function through translocation of the
SLC2A4/GLUT4 (Solute Carrier Family 2 Member 4)
glucose transporter to the cell surface post-insulin signal-
ing effect.21,22 The analysis of the present findings of the
current study demonstrated that the expression of the dys-
regulated gene is controlled by many factors such as
transcription factors, cellular kinases, growth factors and
cytokines such as IL6, TNF, and LEP, and all of them are
involved in consequence of the biological process, path-
ways and diseases associated with T2DM, as we discussed
further in next paragraphs.
The canonical pathway analysis by the core analysis of
IPA (Figure 1) indicated several critical signaling path-
ways involved in the pathogenesis of T2DM and its
comorbidities, such as Retinoid X Receptors (RXRs),
and Acute Phase Response Signaling in the dataset of T2
DM (Table 3, and supplementary Tables S2–S7). RXRs
are nuclear receptors that affect biologic functions such as
lipid metabolism, molecular transport, and small molecule
biochemistry. Activation of RXR is involved in cholesterol
efflux in macrophages through an effect by the following
DRGs of apolipoproteins family; APOE, APOC1, APOC2,
APOC4, while inhibiting APOA5. In hepatocytes, activa-
tion of APOA4 enhances cholesterol efflux. The apolipo-
protein family is transporters that are involved in lipid
metabolism, which altered in diabetes and predisposed to
several disorders such as atherosclerosis and cardiovascu-
lar diseases.23 Furthermore, TNF alpha is one of the DRGs
which is involved in the transport of lipids, steroids, and
efflux of cholesterol. TNF uses different signaling path-
ways such as NFKBIA, and P38MAPK to exert its effect
on lipid transport.24 Such data are supported with the
related functions observed in the present study such as
fat acid metabolism, and lipolysis (Figure S2), and are
interconnected to hypertriglyceridemia as a top disease
related to metabolic disorder and considered as the leading
platform and risk factor for multiple disorders such as
cardiovascular disorders, and progressive neurological dis-
orders (Table 5). The data of the present study revealed
another nuclear receptor that is the Farnesoid X Receptor
(FXR). The FXR is a member of the nuclear family of
receptors and has emerged as a critical player in the con-
trol of numerous metabolic pathways such as a sensor of
bile acid and its regulation (Figure 2). Bile acid receptor
plays a vital role in fat and glucose metabolism.25 The
activation of the membrane G-protein receptor 5 (TGR5)
by bile acids is associated with metabolic actions such as
ameliorating insulin resistance via GLP-1 secretion.26
Furthermore, the acute phase response pathway is one of
the significant pathways observed in the current dataset. The
pathway and its molecules are involved in inflammation
included upregulated proteins via NFKB (Nuclear Factor
Kappa B) as an upstream regulator, which is connected with
2761 nodes and could elucidate the plethoric effects of the
acute phase response signaling pathway. One of these disor-
ders associated with acute inflammatory response is the
damage of the kidney. (Figure 4A and B) displays the pathway
which identifies that TNF and IL6 are upstream regulators
mainly via binding of TNF to TNF receptors at the plasma
membrane where it activates a cascade of nuclear factors such
as jun (Jun Proto-Oncogene), Ep300 (E1A Binding Protein
P300), NF-kB (Nuclear Factor Kappa B), and NF-IL6 which
in turn activates downstream targets of several proteins. The
following up-regulated proteins as downstream targets are;
Complement factor B; CFB [a marker of acute injury in
sepsis],27 Angiotensinogen; AGT [a biomarker of diabetic
nephropathy],28 Interleukin 6; IL6 [a biomarker of ischemic
acute kidney injury, diabetic nephropathy, IgA nephropathy,
and lupus nephritis],29 and Complement component 4, bind-
ing protein, alpha and beta (CA4/C4B) [IgA nephropathy],
Intercellular adhesion molecule 1 (ICAM1) [a biomarker of
glomerulonephritis],30 Tumor necrosis factor (TNF) [a bio-
marker of nephropathies, including immune complex-
mediated glomerulonephritis],31 and Vitamin D Binding
Protein (GC) [a biomarker of diabetic nephropathy],28 all are
involved in the damage of the kidney.
Numerous essential metals are essential for the biological
functions of several enzymes, proteins, and transcriptional
regulators. It is also vital in many biochemical reactions
for cell functions in different tissues. For instance, Zn,
Mg, and Mn are cofactors of several enzymes that
participated in various biological pathways. Zn is implicated
in the biosynthesis and secretion of insulin hormone from the
beta-cells of the pancreas. Likewise, Cr augments the activity
of insulin receptors on muscle cells, which increases the
insulin-stimulated glucose uptake.32 Several studies have
described the pathogenic role of some essential metals
might harmfully disturb pancreatic functions that lead to
the development of diabetes.32 The data set of the current
study showed that many DRGs is involved in increased
prediction to amount of metal ions in T2DM such as CCL2
(C-C Motif Chemokine Ligand 2), F2 (Thrombin), FN1
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(Fibronectin 1), GCG (Glucagon), GHRL (Ghrelin And
Obestatin Prepropeptide), APOE, APOC3, AGT, TTR
(Transthyretin), TNF, PYY (Peptide YY), PTH
(Parathyroid Hormone), PPBP (Pro-Platelet Basic Protein),
PLG (Plasminogen), ORM1 (Orosomucoid 1), ICAM1
(Intercellular adhesion molecule 1) as shown in (Figure 3).
For example, TNF regulates the transport of divalent metals
such as Zinc in cells, via the control of ZIP-importers and
metallothionein gene expression.33
Complications observed with T2DM include disorders
affecting the heart, blood vessels, nerves, eyes, liver, and
kidneys.34 Hyperglycemia and insulin resistance have been
reported as crucial players in the development of
microvascular and macrovascular complications, including
atherosclerosis.35 Overproduction of ROS species of
endothelial dysfunction and inflammation precipitates the
development of diabetic vascular disease.36,37 Close analysis
of the data set (Figure S7b), shows the metabolite KNG1
(Kininogen 1) having a direct positive relationship of regula-
tion for ROS generation,38 while FN1 (Fibronectin 1) regu-
lates endothelial cell proliferation,39 F2 (Coagulation factor
II) regulates endothelial cell function such as apoptosis40 and
PLG (Plasminogen) negatively regulates inflammation.41 In
attempting to monitor the onset of diabetic vascular disease,
over-expression of KNG1, FNI, F2, and PLG could serve as
prognostic biomarkers to monitor early vascular complica-
tions. Moreover, therapeutic applications to counteract vas-
cular compromise, resolving of oxidative stress in T2DM
patients could be achieved by regulating the expression of
APOA1 which inhibits oxidative stress42 and RETN (resis-
tin) which regulates the inflammatory response.43
Amyloidosis is a group of diseases in which misfolded
proteins that result in progressive organ damage are formed
in different tissues (Table 4). The clinical presentation
depends on its location, and the liver, kidney, and heart are
commonly affected (Table S9), causing liver cirrhosis,
nephrotic syndrome, and heart failure, respectively.44
Several disorders were documented in the present study
that dysfunction of the endothelium is considered as
a crucial component in the pathogenesis of vascular disease
including apoptosis, and oxidative stress (Figure S7b), which
eventually leads to the development of diabetic-related com-
plications such as atherosclerosis, diabetic retinopathy, and
nephropathy.45 The damage of the genitourinary system
includes several disorders such as urinary tract infection,
abscess, chronic kidney disease, nephrotic syndrome, and
urinary bladder, and urethral disorders.46 Disorders related
to degranulation of cells, such as the chemotactic activity of
neutrophils with a reduction in the phagocytosis and bacter-
icidal activity (Figure S1) from diabetic patients is impaired,
which predispose to infections .47 Further, we demonstrated
increased activation of leukocytes (Table 5) with increased
release of inflammatory sets of proteins such as IL6, and
TNF, which could play an important role in inflammatory
disorders (Figure 4A and B) associated with diabetes such as
diabetic nephropathy .48
The coagulation pathway (Figure S7a) plays a critical
role in the pathogenesis of cardiovascular disease in patients
with neuropathy.49 Many diabetes patients die of cardiovas-
cular complications. The examination of Figures S7a showed
manymetabolites that affect the coagulation in some fashion.
INS regulates vascularization; APOH, F2, and ICAM regu-
late platelet activation and adhesion; AGT regulates blood
vessel contraction; TNF and CCL2 regulate blood chemo-
kine in circulation; F9 regulates onset Hemophilia B, and
PON1 inhibits onset cardiovascular disease. Directions of
therapeutic goals should aim at monitoring and decreasing
over-expression of the metabolites contributing to coagula-
tion diseases and increasing the counterattack of PON1
(Paraoxonase 1) to prevent cardiovascular morbidity.50
Other cellular processes plagued by T2DM patients include
compromised wound healing, which is regulated by TNF and
LEP metabolites; regulating their over-expression could
resolve wound healing complications.51
Insulin action pathway networks identified dysregulation
of cellular processes such as glucose and lipid metabolism,
which plays a vital role in the pathogenesis of T2DM
(Figure S7 b-d). Monitoring the coupled expression of dysre-
gulated proteins such as IL6, INS, LEP, IAPP (Islet Amyloid
Polypeptide), AGT, TNF, CCL2, GHRL, KNG1 (Kininogen
1), GCG, RETN, and C3 (Complement C3) could be used as
a predictive biomarker of T2DM comorbidities. For instance,
AGT (angiotensinogen) plays an essential role in counteracting
both the cardiovascular and non-cardiovascular actions of
AngII.52 Recent data have revealed that chronic administration
of Ang 11 improves the action of insulin in glucose and lipid
metabolism in obese mice.53 Potential mechanisms of this
beneficial effect included activation of insulin signaling, inhi-
bition of the adverse actions ofAngII, and augmented transport
of insulin to the target tissues.54,55
We observed an intersection between canonical signaling
in T2DM and several DRGs that are tangled in neurological
diseases, metabolic disorders, connective tissue disorders,
immunodeficiency, and renal injuries associated with cellular
functions and canonical pathways (Figure 9a-d). These com-
munications are mediated through several factors, such as
Cheema et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2020:132428
 
D
ia
be
te
s,
 M
et
ab
ol
ic 
Sy
nd
ro
m
e 
an
d 
O
be
sit
y:
 T
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
89
.2
11
.2
26
.2
42
 o
n 
18
-J
ul
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
NFκB, Akt, ERK (extracellular signal-regulated kinases),
TNF, and IL6. These factors were identified for their con-
tributions in various diseases. Such networks indicate the
complexity of the disorders associated with T2DM in terms
of the target genes and their proteins on the different biolo-
gical, cellular, and molecular functions which interact to
cause a particular disorder. Even the complexity is evident
in the current study as we identified in some examples that
the upstream regulators affect abundant molecules such as
growth factors like leptin; cytokines like TNF, and IL6;
transcription factors such as HIFA, STAT, CEBPA, NFκB;
and several kinases such as ERK, mTOR, AKT, and others.
Gathering information’s of the DRGs of the dataset,
and their role in the various biological process with asso-
ciated comorbidities in T2DM could help in understanding
the pathogenesis of various disorders, enhance the utility
of these genes as biomarkers for prediction, prognosis,
complication and response to treatment, and design of
new drugs that can be used in management.
Using the analysis of current data integration, we were
able to answer some questions of interest. For example,
TNF as one of the upstream regulators that are involved in
rheumatoid arthritis, and the clinical utility of Adalimumab
as antibody and binder to TNF target, could be used for the
treatment of active rheumatoid arthritis, which is predicted
to inhibit TNF as a target.56 Another question, which dis-
ease states could develop based on the activation of the
acute phase response signalling signaling pathway in
T2DM, the answer, for example, could be involved in the
damage of the kidney, immunologic, and neurological dis-
orders (Figures 4, 9A and C). STAT3 as an upstream reg-
ulator regulates 15 downstream target genes of the dataset
and STAT3 could be involved in disorders related to inflam-
matory disorders such as connective tissues,57 vascular dis-
orders such as atherosclerosis, angiogenesis,58 neurological
disorders such as Alzheimer’s disorders59 and others based
on the downstream target of the DRGs (Table 5, Figure 5).
We analyzed the pathways, functions, diseases, and regula-
tors to understand which gene or genes of that dataset could
be used to monitor the prognosis, diagnosis, and efficacy of
a particular disorder such as hypertension (IL6, TNF) for
diagnosis of hypertension, while CCL2, IL6, LEP, and HPX
for the efficacy of hypertension management, and, athero-
sclerosis and hemophilia (Figure 8, and Figure S7a). For
example, ANG could be used to monitor the efficacy of
Aliskiren and Irbesartan in the treatment of T2DM asso-
ciated with renal disorders.60,61
In summary, the incorporation of metabolomics and
proteomics data through integrative pathway analysis
using different tools would help in understanding the role
of various biomarkers in the identification of the biological
processes, pathways, and pathophysiology that are asso-
ciated with the comorbidities of T2DM. We identified the
most commonly expressed genes of the study are the fol-
lowing TNF, IL6, LEP, AGT, APOE, F2, SPP1, RETN, and
INS that could be used as potential prognostic biomarkers.
The data recognized that IL6 is the top regulator of the
DRGs, followed by LEP. LXR/RXR and acute phase
response signalling pathways are dominant pathways
involved in renal damage, insulin resistance, dyslipidemia,
and cardiovascular disorders. We identified the role of
upstream regulators such as STAT3 as a transcription factor
that is involved in connective tissue disorders and athero-
sclerosis as it targets many proteins involved in such dis-
orders. ANG could be used as an efficacy biomarker of
renal disorders. TNF is involved in the regulation of metals
such as Zinc, which affects B-cell functions and insulin
secretion. Therefore, such information could help to recog-
nize those patients at higher risk for a specific complication
and its response to a particular class of anti-diabetic drugs.
Prospective studies should be performed to validate the
results obtained from the current work for the utility of the
biomarkers using clinical studies.
A limitation of this study was a difference in the mean
age of the control and diabetic: the age of the patents is older
than the control, which could affect results. Therefore, we
did an AUC analysis of some target biomarkers, as shown in
supplementary Table 1, and previously published.5,6 The
data showed that these markers were differentially
expressed in the diabetic cohort, regardless of the age of
the individual.
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